Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in Healthy Volunteers and Pulmonary Arterial Hypertension
NCT06649110Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of LTP001 in pulmonary arterial hypertension (PAH), sponsored by Novartis. Started Oct 2024; status: recruiting.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06649110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649110.